Neuphoria Therapeutics Celebrates a Significant Milestone
Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a clinical-stage biotechnology company focused on developing innovative treatments for neuropsychiatric disorders, is gearing up for an exciting event as it prepares to ring the Nasdaq Opening Bell in New York City. This notable occasion symbolizes the company's successful transition into the public market and highlights its commitment to advancing healthcare solutions.
Leadership Team's Involvement in the Ceremony
At this celebratory event, Spyros Papapetropoulos, MD, PhD, who serves as the company's President and Chief Executive Officer, will be joined by the board of directors, management team, and advisors. Their presence underscores the dedication and hard work put into positioning Neuphoria for a fruitful future. Dr. Papapetropoulos expressed his gratitude for the team's efforts, stating, "We are truly honored to ring the Nasdaq Opening Bell and celebrate our hard work and redomiciliation to the US. Our commitment to creating impactful therapies remains steadfast as we seek to transform the lives of those affected by neuropsychiatric conditions."
Broadcast Details for the Ceremony
Those interested can tune in to the live broadcast of the Nasdaq Opening Bell ceremony, which will commence at 9:15 a.m. Eastern Time. The event can be accessed on various platforms, ensuring fans and supporters can share in this historic moment for Neuphoria Therapeutics.
About Neuphoria Therapeutics Inc.
As a company dedicated to addressing the complexities of neuropsychiatric disorders, Neuphoria Therapeutics is making strides with its lead drug candidate, BNC210. This oral therapy is designed specifically for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Distinctly, BNC210 is a selective negative allosteric modulator of the ?7 nicotinic acetylcholine receptor, promising a well-tolerated solution aimed at restoring balance in neurotransmitter systems, thereby offering fast relief from anxiety without common side effects like sedation or cognitive impairment.
Pioneering Collaborative Efforts
In addition to its innovative therapies, Neuphoria is also engaged in a strategic partnership with Merck & Co., Inc., focusing on emerging treatments for cognitive deficits in Alzheimer's disease and other neurological conditions. This collaboration marks a step forward in harnessing the combined expertise of both companies to enhance patient outcomes. Moreover, Neuphoria’s pipeline is robust, including next-generation therapies targeting the ?7 nicotinic acetylcholine receptor and Kv3.1/3.2 preclinical programs that are currently in development stages.
Company Contact Information
For further information, please contact:
General Inquiries:
Spyridon (Spyros) Papapetropoulos
info@neuphoriatx.com
Investor Relations:
Kevin Gardner
kgardner@lifesciadvisors.com
Investor Relations:
Chris Calabrese
ccalabrese@lifesciadvisors.com
Frequently Asked Questions
1. What is Neuphoria Therapeutics Inc. known for?
Neuphoria Therapeutics focuses on developing therapies for neuropsychiatric disorders, emphasizing innovative treatments like BNC210.
2. When will Neuphoria ring the Nasdaq Opening Bell?
Neuphoria is set to ring the Nasdaq Opening Bell to celebrate its market debut, an event anticipated to bring attention to its mission.
3. What is BNC210?
BNC210 is an oral therapy developed by Neuphoria for treating social anxiety disorder and post-traumatic stress disorder.
4. Is Neuphoria involved in any partnerships?
Yes, Neuphoria has a strategic partnership with Merck & Co., Inc., focusing on innovative treatments for cognitive deficits.
5. How can I contact Neuphoria for more information?
For inquiries, you can contact Spyridon (Spyros) Papapetropoulos or reach out to the investor relations team via the provided email addresses.
